High Growth Tech And 2 Other Promising Stocks For Your Portfolio

In a week marked by geopolitical tensions and consumer spending concerns, major U.S. stock indexes experienced declines despite reaching record highs earlier, with the S&P 500 and Nasdaq Composite both ending lower amid tariff fears and economic uncertainties. In this environment, identifying high-growth tech stocks that can navigate such volatility becomes crucial for investors seeking to balance potential returns with the broader market sentiment.

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	35.41%	39.86%	★★★★★★
Clinuvel Pharmaceuticals	21.39%	26.17%	★★★★★★
Yggdrazil Group	30.20%	87.10%	★★★★★★
eWeLLLtd	24.94%	24.24%	★★★★★★
Travere Therapeutics	27.14%	66.43%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
AVITA Medical	27.78%	55.33%	★★★★★★
Alnylam Pharmaceuticals	21.83%	59.08%	★★★★★★
Mental Health TechnologiesLtd	21.91%	92.81%	★★★★★★
Delton Technology (Guangzhou)	20.25%	29.52%	★★★★★★

Click here to see the full list of 1196 stocks from our High Growth Tech and AI Stocks screener.

Let’s review some notable picks from our screened stocks.

Simply Wall St Growth Rating: ★★★★★★

Overview: PharmaResearch Co., Ltd. is a South Korean biopharmaceutical company that operates with its subsidiaries, and it has a market capitalization of ₩2.99 trillion.

Operations: PharmaResearch Co., Ltd. generates revenue primarily from its pharmaceuticals segment, which contributed ₩317 billion.

PharmaResearch’s robust R&D investment, which consistently aligns with or exceeds industry standards, underscores its commitment to innovation and sector leadership. Last year alone, the company allocated $1.2 billion to R&D activities, representing a significant percentage of its revenue. This focus on research not only fuels PharmaResearch’s pipeline but also enhances its competitive edge in biotechnology—a field where rapid advancements are critical. With earnings growth outpacing the industry at 36.8% compared to biotech’s average of 22.3%, and projected annual revenue increases of 23.4%, PharmaResearch is well-positioned for sustained growth. These figures highlight the company’s adeptness in not only generating high-quality earnings but also in maintaining a trajectory that promises continued market relevance and investor interest.

KOSDAQ:A214450 Revenue and Expenses Breakdown as at Feb 2025

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kuaishou Technology is an investment holding company that offers live streaming, online marketing, and other services in China, with a market capitalization of HK$249.76 billion.